

Peripheral Arterial Disease (PAD) Therapeutics Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/P0B66B688D6EEN.html>

Date: March 2022

Pages: 66

Price: US\$ 3,250.00 (Single User License)

ID: P0B66B688D6EEN

Abstracts

Peripheral artery disease (PAD) is a narrowing of the arteries other than those that supply the heart or the brain. When narrowing occurs in the heart, it is called coronary artery disease, while, in the brain, it is called cerebrovascular disease. Peripheral artery disease most commonly affects the legs, but other arteries may also be involved. The classic symptom is leg pain when walking which resolves with rest, known as intermittent claudication. Other symptoms including skin ulcers, bluish skin, cold skin, or poor nail and hair growth may occur in the affected leg. Complications may include an infection or tissue death which may require amputation; coronary artery disease, or stroke.[3] Up to 50% of cases of PAD are without symptoms.

This report contains market size and forecasts of Peripheral Arterial Disease (PAD) Therapeutics in Global, including the following market information:

Global Peripheral Arterial Disease (PAD) Therapeutics Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Peripheral Arterial Disease (PAD) Therapeutics market was valued at 3025.1 million in 2021 and is projected to reach US\$ 4289.2 million by 2028, at a CAGR of 5.1% during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Anti-Platelet Drugs Segment to Reach \$ Million by 2028, with a % CAGR in next six

years.

The global key manufacturers of Peripheral Arterial Disease (PAD) Therapeutics include AstraZeneca Plc. (UK), Bayer HealthCare Pharmaceuticals (Germany), Bristol-Myers Squibb Company (US), Merck & Co., Inc. (US), Proteon Therapeutics, Inc. (US), Sanofi S.A. (France), Symic Bio, Inc. (US), TheraVasc Inc. (US) and AnGes MG, Inc. (Japan), etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Peripheral Arterial Disease (PAD) Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Peripheral Arterial Disease (PAD) Therapeutics Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Peripheral Arterial Disease (PAD) Therapeutics Market Segment Percentages, by Type, 2021 (%)

Anti-Platelet Drugs

Dual Antiplatelet Therapy Drugs

Others

Global Peripheral Arterial Disease (PAD) Therapeutics Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Peripheral Arterial Disease (PAD) Therapeutics Market Segment Percentages, by Application, 2021 (%)

Hospitals

Clinics

Others

Global Peripheral Arterial Disease (PAD) Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Peripheral Arterial Disease (PAD) Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Peripheral Arterial Disease (PAD) Therapeutics revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Peripheral Arterial Disease (PAD) Therapeutics revenues share in

global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

AstraZeneca Plc. (UK)

Bayer HealthCare Pharmaceuticals (Germany)

Bristol-Myers Squibb Company (US)

Merck & Co., Inc. (US)

Proteon Therapeutics, Inc. (US)

Sanofi S.A. (France)

Symic Bio, Inc. (US)

TheraVasc Inc. (US)

AnGes MG, Inc. (Japan)

Athersys, Inc. (US)

Betagenon AB (Sweden)

miRagen Therapeutics, Inc. (US)

Multi Gene Vascular Systems Ltd (Israel)

ViroMed Co. Ltd. (Korea)

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Peripheral Arterial Disease (PAD) Therapeutics Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Peripheral Arterial Disease (PAD) Therapeutics Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL PERIPHERAL ARTERIAL DISEASE (PAD) THERAPEUTICS OVERALL MARKET SIZE

- 2.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size: 2021 VS 2028
- 2.2 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Peripheral Arterial Disease (PAD) Therapeutics Players in Global Market
- 3.2 Top Global Peripheral Arterial Disease (PAD) Therapeutics Companies Ranked by Revenue
- 3.3 Global Peripheral Arterial Disease (PAD) Therapeutics Revenue by Companies
- 3.4 Top 3 and Top 5 Peripheral Arterial Disease (PAD) Therapeutics Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Peripheral Arterial Disease (PAD) Therapeutics Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Peripheral Arterial Disease (PAD) Therapeutics Players in Global Market
 - 3.6.1 List of Global Tier 1 Peripheral Arterial Disease (PAD) Therapeutics Companies

3.6.2 List of Global Tier 2 and Tier 3 Peripheral Arterial Disease (PAD) Therapeutics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Markets, 2021 & 2028

4.1.2 Anti-Platelet Drugs

4.1.3 Dual Antiplatelet Therapy Drugs

4.1.4 Others

4.2 By Type - Global Peripheral Arterial Disease (PAD) Therapeutics Revenue & Forecasts

4.2.1 By Type - Global Peripheral Arterial Disease (PAD) Therapeutics Revenue, 2017-2022

4.2.2 By Type - Global Peripheral Arterial Disease (PAD) Therapeutics Revenue, 2023-2028

4.2.3 By Type - Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Peripheral Arterial Disease (PAD) Therapeutics Market Size, 2021 & 2028

5.1.2 Hospitals

5.1.3 Clinics

5.1.4 Others

5.2 By Application - Global Peripheral Arterial Disease (PAD) Therapeutics Revenue & Forecasts

5.2.1 By Application - Global Peripheral Arterial Disease (PAD) Therapeutics Revenue, 2017-2022

5.2.2 By Application - Global Peripheral Arterial Disease (PAD) Therapeutics Revenue, 2023-2028

5.2.3 By Application - Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Peripheral Arterial Disease (PAD) Therapeutics Market Size, 2021 & 2028

6.2 By Region - Global Peripheral Arterial Disease (PAD) Therapeutics Revenue & Forecasts

6.2.1 By Region - Global Peripheral Arterial Disease (PAD) Therapeutics Revenue, 2017-2022

6.2.2 By Region - Global Peripheral Arterial Disease (PAD) Therapeutics Revenue, 2023-2028

6.2.3 By Region - Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Peripheral Arterial Disease (PAD) Therapeutics Revenue, 2017-2028

6.3.2 US Peripheral Arterial Disease (PAD) Therapeutics Market Size, 2017-2028

6.3.3 Canada Peripheral Arterial Disease (PAD) Therapeutics Market Size, 2017-2028

6.3.4 Mexico Peripheral Arterial Disease (PAD) Therapeutics Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Peripheral Arterial Disease (PAD) Therapeutics Revenue, 2017-2028

6.4.2 Germany Peripheral Arterial Disease (PAD) Therapeutics Market Size, 2017-2028

6.4.3 France Peripheral Arterial Disease (PAD) Therapeutics Market Size, 2017-2028

6.4.4 U.K. Peripheral Arterial Disease (PAD) Therapeutics Market Size, 2017-2028

6.4.5 Italy Peripheral Arterial Disease (PAD) Therapeutics Market Size, 2017-2028

6.4.6 Russia Peripheral Arterial Disease (PAD) Therapeutics Market Size, 2017-2028

6.4.7 Nordic Countries Peripheral Arterial Disease (PAD) Therapeutics Market Size, 2017-2028

6.4.8 Benelux Peripheral Arterial Disease (PAD) Therapeutics Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Peripheral Arterial Disease (PAD) Therapeutics Revenue, 2017-2028

6.5.2 China Peripheral Arterial Disease (PAD) Therapeutics Market Size, 2017-2028

6.5.3 Japan Peripheral Arterial Disease (PAD) Therapeutics Market Size, 2017-2028

6.5.4 South Korea Peripheral Arterial Disease (PAD) Therapeutics Market Size, 2017-2028

6.5.5 Southeast Asia Peripheral Arterial Disease (PAD) Therapeutics Market Size, 2017-2028

6.5.6 India Peripheral Arterial Disease (PAD) Therapeutics Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Peripheral Arterial Disease (PAD) Therapeutics Revenue, 2017-2028

6.6.2 Brazil Peripheral Arterial Disease (PAD) Therapeutics Market Size, 2017-2028

6.6.3 Argentina Peripheral Arterial Disease (PAD) Therapeutics Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Revenue, 2017-2028

6.7.2 Turkey Peripheral Arterial Disease (PAD) Therapeutics Market Size, 2017-2028

6.7.3 Israel Peripheral Arterial Disease (PAD) Therapeutics Market Size, 2017-2028

6.7.4 Saudi Arabia Peripheral Arterial Disease (PAD) Therapeutics Market Size, 2017-2028

6.7.5 UAE Peripheral Arterial Disease (PAD) Therapeutics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 AstraZeneca Plc. (UK)

7.1.1 AstraZeneca Plc. (UK) Corporate Summary

7.1.2 AstraZeneca Plc. (UK) Business Overview

7.1.3 AstraZeneca Plc. (UK) Peripheral Arterial Disease (PAD) Therapeutics Major Product Offerings

7.1.4 AstraZeneca Plc. (UK) Peripheral Arterial Disease (PAD) Therapeutics Revenue in Global Market (2017-2022)

7.1.5 AstraZeneca Plc. (UK) Key News

7.2 Bayer HealthCare Pharmaceuticals (Germany)

7.2.1 Bayer HealthCare Pharmaceuticals (Germany) Corporate Summary

7.2.2 Bayer HealthCare Pharmaceuticals (Germany) Business Overview

7.2.3 Bayer HealthCare Pharmaceuticals (Germany) Peripheral Arterial Disease (PAD) Therapeutics Major Product Offerings

7.2.4 Bayer HealthCare Pharmaceuticals (Germany) Peripheral Arterial Disease (PAD) Therapeutics Revenue in Global Market (2017-2022)

7.2.5 Bayer HealthCare Pharmaceuticals (Germany) Key News

7.3 Bristol-Myers Squibb Company (US)

7.3.1 Bristol-Myers Squibb Company (US) Corporate Summary

7.3.2 Bristol-Myers Squibb Company (US) Business Overview

7.3.3 Bristol-Myers Squibb Company (US) Peripheral Arterial Disease (PAD) Therapeutics Major Product Offerings

7.3.4 Bristol-Myers Squibb Company (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue in Global Market (2017-2022)

- 7.3.5 Bristol-Myers Squibb Company (US) Key News
- 7.4 Merck & Co., Inc. (US)
 - 7.4.1 Merck & Co., Inc. (US) Corporate Summary
 - 7.4.2 Merck & Co., Inc. (US) Business Overview
 - 7.4.3 Merck & Co., Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Major Product Offerings
 - 7.4.4 Merck & Co., Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue in Global Market (2017-2022)
 - 7.4.5 Merck & Co., Inc. (US) Key News
- 7.5 Proteon Therapeutics, Inc. (US)
 - 7.5.1 Proteon Therapeutics, Inc. (US) Corporate Summary
 - 7.5.2 Proteon Therapeutics, Inc. (US) Business Overview
 - 7.5.3 Proteon Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Major Product Offerings
 - 7.5.4 Proteon Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue in Global Market (2017-2022)
 - 7.5.5 Proteon Therapeutics, Inc. (US) Key News
- 7.6 Sanofi S.A. (France)
 - 7.6.1 Sanofi S.A. (France) Corporate Summary
 - 7.6.2 Sanofi S.A. (France) Business Overview
 - 7.6.3 Sanofi S.A. (France) Peripheral Arterial Disease (PAD) Therapeutics Major Product Offerings
 - 7.6.4 Sanofi S.A. (France) Peripheral Arterial Disease (PAD) Therapeutics Revenue in Global Market (2017-2022)
 - 7.6.5 Sanofi S.A. (France) Key News
- 7.7 Symic Bio, Inc. (US)
 - 7.7.1 Symic Bio, Inc. (US) Corporate Summary
 - 7.7.2 Symic Bio, Inc. (US) Business Overview
 - 7.7.3 Symic Bio, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Major Product Offerings
 - 7.7.4 Symic Bio, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue in Global Market (2017-2022)
 - 7.7.5 Symic Bio, Inc. (US) Key News
- 7.8 TheraVasc Inc. (US)
 - 7.8.1 TheraVasc Inc. (US) Corporate Summary
 - 7.8.2 TheraVasc Inc. (US) Business Overview
 - 7.8.3 TheraVasc Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Major Product Offerings
 - 7.8.4 TheraVasc Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue in

Global Market (2017-2022)

7.8.5 TheraVasc Inc. (US) Key News

7.9 AnGes MG, Inc. (Japan)

7.9.1 AnGes MG, Inc. (Japan) Corporate Summary

7.9.2 AnGes MG, Inc. (Japan) Business Overview

7.9.3 AnGes MG, Inc. (Japan) Peripheral Arterial Disease (PAD) Therapeutics Major Product Offerings

7.9.4 AnGes MG, Inc. (Japan) Peripheral Arterial Disease (PAD) Therapeutics

Revenue in Global Market (2017-2022)

7.9.5 AnGes MG, Inc. (Japan) Key News

7.10 Athersys, Inc. (US)

7.10.1 Athersys, Inc. (US) Corporate Summary

7.10.2 Athersys, Inc. (US) Business Overview

7.10.3 Athersys, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Major Product Offerings

7.10.4 Athersys, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue in Global Market (2017-2022)

7.10.5 Athersys, Inc. (US) Key News

7.11 Betagenon AB (Sweden)

7.11.1 Betagenon AB (Sweden) Corporate Summary

7.11.2 Betagenon AB (Sweden) Business Overview

7.11.3 Betagenon AB (Sweden) Peripheral Arterial Disease (PAD) Therapeutics Major Product Offerings

7.11.4 Betagenon AB (Sweden) Peripheral Arterial Disease (PAD) Therapeutics Revenue in Global Market (2017-2022)

7.11.5 Betagenon AB (Sweden) Key News

7.12 miRagen Therapeutics, Inc. (US)

7.12.1 miRagen Therapeutics, Inc. (US) Corporate Summary

7.12.2 miRagen Therapeutics, Inc. (US) Business Overview

7.12.3 miRagen Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Major Product Offerings

7.12.4 miRagen Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue in Global Market (2017-2022)

7.12.5 miRagen Therapeutics, Inc. (US) Key News

7.13 Multi Gene Vascular Systems Ltd (Israel)

7.13.1 Multi Gene Vascular Systems Ltd (Israel) Corporate Summary

7.13.2 Multi Gene Vascular Systems Ltd (Israel) Business Overview

7.13.3 Multi Gene Vascular Systems Ltd (Israel) Peripheral Arterial Disease (PAD) Therapeutics Major Product Offerings

7.13.4 Multi Gene Vascular Systems Ltd (Israel) Peripheral Arterial Disease (PAD) Therapeutics Revenue in Global Market (2017-2022)

7.13.5 Multi Gene Vascular Systems Ltd (Israel) Key News

7.14 ViroMed Co. Ltd. (Korea)

7.14.1 ViroMed Co. Ltd. (Korea) Corporate Summary

7.14.2 ViroMed Co. Ltd. (Korea) Business Overview

7.14.3 ViroMed Co. Ltd. (Korea) Peripheral Arterial Disease (PAD) Therapeutics Major Product Offerings

7.14.4 ViroMed Co. Ltd. (Korea) Peripheral Arterial Disease (PAD) Therapeutics Revenue in Global Market (2017-2022)

7.14.5 ViroMed Co. Ltd. (Korea) Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Peripheral Arterial Disease (PAD) Therapeutics Market Opportunities & Trends in Global Market

Table 2. Peripheral Arterial Disease (PAD) Therapeutics Market Drivers in Global Market

Table 3. Peripheral Arterial Disease (PAD) Therapeutics Market Restraints in Global Market

Table 4. Key Players of Peripheral Arterial Disease (PAD) Therapeutics in Global Market

Table 5. Top Peripheral Arterial Disease (PAD) Therapeutics Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Share by Companies, 2017-2022

Table 8. Global Companies Peripheral Arterial Disease (PAD) Therapeutics Product Type

Table 9. List of Global Tier 1 Peripheral Arterial Disease (PAD) Therapeutics Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Peripheral Arterial Disease (PAD) Therapeutics Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Peripheral Arterial Disease (PAD) Therapeutics Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Peripheral Arterial Disease (PAD) Therapeutics Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Peripheral Arterial Disease (PAD) Therapeutics Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Peripheral Arterial Disease (PAD) Therapeutics Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Peripheral Arterial Disease (PAD) Therapeutics Revenue

(US\$, Mn), 2017-2022

Table 19. By Region - Global Peripheral Arterial Disease (PAD) Therapeutics Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 30. AstraZeneca Plc. (UK) Corporate Summary

Table 31. AstraZeneca Plc. (UK) Peripheral Arterial Disease (PAD) Therapeutics Product Offerings

Table 32. AstraZeneca Plc. (UK) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 33. Bayer HealthCare Pharmaceuticals (Germany) Corporate Summary

Table 34. Bayer HealthCare Pharmaceuticals (Germany) Peripheral Arterial Disease (PAD) Therapeutics Product Offerings

Table 35. Bayer HealthCare Pharmaceuticals (Germany) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 36. Bristol-Myers Squibb Company (US) Corporate Summary

Table 37. Bristol-Myers Squibb Company (US) Peripheral Arterial Disease (PAD) Therapeutics Product Offerings

Table 38. Bristol-Myers Squibb Company (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 39. Merck & Co., Inc. (US) Corporate Summary

Table 40. Merck & Co., Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product Offerings

Table 41. Merck & Co., Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 42. Proteon Therapeutics, Inc. (US) Corporate Summary

Table 43. Proteon Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product Offerings

Table 44. Proteon Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 45. Sanofi S.A. (France) Corporate Summary

Table 46. Sanofi S.A. (France) Peripheral Arterial Disease (PAD) Therapeutics Product Offerings

Table 47. Sanofi S.A. (France) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 48. Symic Bio, Inc. (US) Corporate Summary

Table 49. Symic Bio, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product Offerings

Table 50. Symic Bio, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 51. TheraVasc Inc. (US) Corporate Summary

Table 52. TheraVasc Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product Offerings

Table 53. TheraVasc Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 54. AnGes MG, Inc. (Japan) Corporate Summary

Table 55. AnGes MG, Inc. (Japan) Peripheral Arterial Disease (PAD) Therapeutics Product Offerings

Table 56. AnGes MG, Inc. (Japan) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 57. Athersys, Inc. (US) Corporate Summary

Table 58. Athersys, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product Offerings

Table 59. Athersys, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 60. Betagenon AB (Sweden) Corporate Summary

Table 61. Betagenon AB (Sweden) Peripheral Arterial Disease (PAD) Therapeutics Product Offerings

Table 62. Betagenon AB (Sweden) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 63. miRagen Therapeutics, Inc. (US) Corporate Summary

Table 64. miRagen Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product Offerings

Table 65. miRagen Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 66. Multi Gene Vascular Systems Ltd (Israel) Corporate Summary

Table 67. Multi Gene Vascular Systems Ltd (Israel) Peripheral Arterial Disease (PAD) Therapeutics Product Offerings

Table 68. Multi Gene Vascular Systems Ltd (Israel) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 69. ViroMed Co. Ltd. (Korea) Corporate Summary

Table 70. ViroMed Co. Ltd. (Korea) Peripheral Arterial Disease (PAD) Therapeutics Product Offerings

Table 71. ViroMed Co. Ltd. (Korea) Peripheral Arterial Disease (PAD) Therapeutics Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Peripheral Arterial Disease (PAD) Therapeutics Segment by Type in 2021

Figure 2. Peripheral Arterial Disease (PAD) Therapeutics Segment by Application in 2021

Figure 3. Global Peripheral Arterial Disease (PAD) Therapeutics Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue, 2017-2028 (US\$, Mn)

Figure 7. The Top 3 and 5 Players Market Share by Peripheral Arterial Disease (PAD) Therapeutics Revenue in 2021

Figure 8. By Type - Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share, 2017-2028

Figure 9. By Application - Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share, 2017-2028

Figure 10. By Region - Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share, 2017-2028

Figure 11. By Country - North America Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share, 2017-2028

Figure 12. US Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 13. Canada Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 14. Mexico Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 15. By Country - Europe Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share, 2017-2028

Figure 16. Germany Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 17. France Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 18. U.K. Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 19. Italy Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 20. Russia Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share, 2017-2028

Figure 24. China Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 28. India Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share, 2017-2028

Figure 30. Brazil Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share, 2017-2028

Figure 33. Turkey Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Peripheral Arterial Disease (PAD) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 37. AstraZeneca Plc. (UK) Peripheral Arterial Disease (PAD) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Bayer HealthCare Pharmaceuticals (Germany) Peripheral Arterial Disease (PAD) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Bristol-Myers Squibb Company (US) Peripheral Arterial Disease (PAD)

Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Merck & Co., Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Proteon Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Sanofi S.A. (France) Peripheral Arterial Disease (PAD) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Symic Bio, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. TheraVasc Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. AnGes MG, Inc. (Japan) Peripheral Arterial Disease (PAD) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Athersys, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. Betagenon AB (Sweden) Peripheral Arterial Disease (PAD) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 48. miRagen Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 49. Multi Gene Vascular Systems Ltd (Israel) Peripheral Arterial Disease (PAD) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 50. ViroMed Co. Ltd. (Korea) Peripheral Arterial Disease (PAD) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Peripheral Arterial Disease (PAD) Therapeutics Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/P0B66B688D6EEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P0B66B688D6EEN.html>